{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:25:07Z","timestamp":1790461507264,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Clinical studies show that SARS-CoV-2 vaccination sometimes entails a severe and disabling chronic syndrome termed post-acute-COVID-19-vaccination syndrome (PACVS). PACVS shares similarities with long COVID. Today, PACVS is still not officially recognised as a disease. In contrast, long COVID was registered by health authorities in December 2021. Here, we address possible reasons for that discrepancy. Methods: We analyse whether common symptoms of PACVS have been registered by European pharmacovigilance as adverse vaccination reactions and which consequences have been drawn thereof. Results: (i) PACVS is distinguished from normal vaccination reactions solely by prolonged duration. (ii) Symptom duration is poorly monitored by post-authorisation pharmacovigilance. (iii) PACVS-specific signals were faithfully recorded by pharmacovigilance systems but have not prompted appropriate reactions of health authorities. (iv) The most widely applied SARS-CoV-2 mRNA-vaccine has been modified after roll-out without renewed phase III evaluation; the modification has increased DNA contaminations suspected to extend the spectrum of adverse events. (v) Crossing of pharmacovigilance data with corresponding estimates of applied vaccine doses suggest a PACVS prevalence of 0.003% in the general population. In contrast, occupational surveillance studies suggest a PACVS prevalence of 0.9% in young and middle-aged persons. Conclusions: (a) Denial of official recognition of PACVS is unjustified. (b) PACVS seems to target preferentially young and middle-aged persons. (c) Without official disease recognition, access to public healthcare and welfare services is made difficult for PACVS-affected persons, which creates considerable socio-economic problems. (d) Without official disease recognition, development and evaluation of PACVS therapies is impaired.<\/jats:p>","DOI":"10.3390\/vaccines12121378","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:58:45Z","timestamp":1733482725000},"page":"1378","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Post-Acute COVID-19-Vaccination Syndrome in the Light of Pharmacovigilance"],"prefix":"10.3390","volume":"12","author":[{"given":"Barbara","family":"Platschek","sequence":"first","affiliation":[{"name":"Central Institute of Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University, University Hospital, 40255 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-1033","authenticated-orcid":false,"given":"Fritz","family":"Boege","sequence":"additional","affiliation":[{"name":"Central Institute of Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University, University Hospital, 40255 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154497","DOI":"10.1016\/j.prp.2023.154497","article-title":"COVID-19, post-acute COVID-19 syndrome (PACS, \u201clong COVID\u201d) and post-COVID-19 vaccination syndrome (PCVS, \u201cpost-COVIDvacsyndrome\u201d): Similarities and differences","volume":"246","author":"Scholkmann","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_3","unstructured":"(2024, June 27). EMA Recommends First COVID-19 Vaccine for Authorisation in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu."},{"key":"ref_4","unstructured":"(2024, June 27). React19 Patient-Led Research: Persistent Symptoms Survey #1. Available online: https:\/\/react19.org\/science-and-research\/lit-reviews-and-surveys\/react19-patient-led-research-persistent-symptoms-survey-1."},{"key":"ref_5","unstructured":"(2024, June 27). Woman with \u2018Life-Altering\u2019 Injuries After COVID Vaccine Teams up with U.S. Senators to Demand Answers. Available online: https:\/\/childrenshealthdefense.org\/defender\/brianne-dressen-injuries-astrazeneca-covid-vaccine-senators-demand-answer\/."},{"key":"ref_6","unstructured":"(2024, June 27). Physician \u2018Horribly Injured\u2019 After Pfizer Vaccine Pleads with Top U.S. Public Health Officials for Help\u2014and Gets None. Available online: https:\/\/childrenshealthdefense.org\/defender\/dr-danice-hertz-injured-pfizer-covid-vaccine\/."},{"key":"ref_7","unstructured":"(2024, June 27). Woman Injured by COVID Vaccine Pleads with Health Agencies for Help, as Local News Agency Kills Story After Pressure From Pfizer. Available online: https:\/\/childrenshealthdefense.org\/defender\/kristi-dobbs-injured-pfizer-covid-vaccine-local-news-agency-kills-story\/."},{"key":"ref_8","first-page":"364","article-title":"In rare cases, coronavirus vaccines may cause Long Covid\u2013like symptoms","volume":"375","author":"Vogel","year":"2022","journal-title":"Sci. Insid."},{"key":"ref_9","unstructured":"Mandavilli, A. (2024, May 06). Thousands Believe COVID Vaccines Harmed Them. Is Anyone Listening?. New York Times, Available online: https:\/\/www.nytimes.com\/2024\/05\/03\/health\/covid-vaccines-side-effects.html."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Safavi, F., Gustafson, L., Walitt, B., Lehky, T., Dehbashi, S., Wiebold, A., Mina, Y., Shin, S., Pan, B., and Polydefkis, M. (2022). Neuropathic symptoms with SARS-CoV-2 vaccination. medRxiv [Preprint].","DOI":"10.1101\/2022.05.16.22274439"},{"key":"ref_11","unstructured":"(2024, June 27). European Medicines Agency, COVID-19 Vaccines Safety Update, November 2022 Rev. 3. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccines-safety-update-10-november-2022_en.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Semmler, A., Mundorf, A.K., Kuechler, A.S., Schulze-Bosse, K., Heidecke, H., Schulze-Forster, K., Schott, M., Uhrberg, M., Weinhold, S., and Lackner, K.J. (2023). Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers. Vaccines, 11.","DOI":"10.20944\/preprints202309.0113.v1"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Krumholz, H.M., Wu, Y., Sawano, M., Shah, R., Zhou, T., Arun, A.S., Khosla, P., Kaleem, S., Vashist, A., and Bhattacharjee, B. (2023). Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization. medRxiv [Preprint].","DOI":"10.1101\/2023.11.09.23298266"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mundorf, A.K., Semmler, A., Heidecke, H., Schott, M., Steffen, F., Bittner, S., Lackner, K.J., Schulze-Bosse, K., Pawlitzki, M., and Meuth, S.G. (2024). Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). Vaccines, 12.","DOI":"10.20944\/preprints202406.0848.v1"},{"key":"ref_15","unstructured":"(2024, June 27). EudraVigilance. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance."},{"key":"ref_16","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online:  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf."},{"key":"ref_17","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-epar-product-information_en.pdf."},{"key":"ref_18","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-epar-product-information_en.pdf."},{"key":"ref_19","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jcovden-epar-product-information_en.pdf."},{"key":"ref_20","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nuvaxovid-epar-product-information_en.pdf."},{"key":"ref_21","unstructured":"(2024, June 27). EPAR Product Information Sheets, Annex 1, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"Adverse Event Monitoring (2024, August 07). Browse Under the Letter \u201cC\u201d LIKE Covid-19 Vaccines and the Respective Vaccine Brand. Available online: https:\/\/www.adrreports.eu\/en\/search_subst.html."},{"key":"ref_24","unstructured":"(2024, September 25). EudraVigilance Access Policy. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-4_en.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Attia, S., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., and Klugar, M. (2021). Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071428"},{"key":"ref_26","unstructured":"(2024, June 27). COVID-19 Vaccine Safety Update, COMIRNATY BioNTech Manufacturing GmbH, 06. October 2021. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-comirnaty-6-october-2021_en.pdf."},{"key":"ref_27","unstructured":"(2024, June 27). COMIRNATY Procedural Steps Taken and Scientific Information After the Authorisation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/comirnaty-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf."},{"key":"ref_28","unstructured":"(2024, November 03). Centrum Lareb: Long COVID-Like Symptoms Following Immunization with COVID-19 Vaccines. Available online: https:\/\/www.lareb.nl\/media\/g54d3xrc\/signals_2024_long-covid-like-symptoms-after-covid-19-vaccination_website.pdf."},{"key":"ref_29","first-page":"55205","article-title":"Myocarditis, Coagulopathy, and Small Fibre, Sensory, and Multiple Cranial Nerve Neuropathy Complicating BNT162b2 Vaccination: A Case Report","volume":"16","author":"Finsterer","year":"2024","journal-title":"Cureus"},{"key":"ref_30","unstructured":"(2024, June 27). Assessment Report EMA\/707383\/2020 Corr. 2. (2021). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/comirnaty-epar-public-assessment-report_en.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Speicher, D.J., Rose, J., Gutschi, L.M., Wiseman, D.M., and McKernan, K. (2023). DNA fragments detected in monovalent and bivalent Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. Researchgate [Preprint].","DOI":"10.31219\/osf.io\/mjc97"},{"key":"ref_32","unstructured":"(2024, June 27). South Carolina Legislature Online, 12 September 2023, Available online: https:\/\/www.scstatehouse.gov\/CommitteeInfo\/SenateMedicalAffairsCommittee\/PandemicPreparedness\/Phillip-Buckhaults-SC-Senate-09122023-final.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, B., and Kirchner, J.O. (2024). Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty\u00ae. Methods Protoc., 7.","DOI":"10.20944\/preprints202411.1912.v2"},{"key":"ref_34","unstructured":"(2024, June 27). Information for Healthcare Professionals, 22 December 2023. Available online: https:\/\/www.pei.de\/SharedDocs\/Downloads\/EN\/newsroom-en\/notification\/231222-testing-mrna-vaccinas-dna-contamination.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.nano.2016.12.014","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s12035-021-02696-0","article-title":"Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?","volume":"59","author":"Theoharides","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_37","unstructured":"(2024, October 09). OECD, Enhancing Public Trust in COVID-19 Vaccination. Available online: https:\/\/one.oecd.org\/document\/COM\/DELSA\/GOV(2021)1\/En\/pdf."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gopalaswamy, R., Aravindhan, V., and Subbian, S. (2024). The Ambivalence of Post COVID-19 Vaccination Responses in Humans. Biomolecules, 14.","DOI":"10.3390\/biom14101320"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Thoma, M., Froehlich, L., Hattesohl, D.B.R., Quante, S., Jason, L.A., and Scheibenbogen, C. (2023). Why the Psychosomatic View on Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome Is Inconsistent with Current Evidence and Harmful to Patients. Medicina, 60.","DOI":"10.3390\/medicina60010083"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autneu.2018.03.004","article-title":"Cognitive and psychological issues in postural tachycardia syndrome","volume":"215","author":"Raj","year":"2018","journal-title":"Auton Neurosci"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fneur.2020.00342","article-title":"Which Method for Diagnosing Small Fiber Neuropathy?","volume":"5","author":"Fabry","year":"2020","journal-title":"Front Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104547","DOI":"10.1016\/j.nurpra.2023.104547","article-title":"Small Fiber Neuropathy: A Clinical and Practical Approach","volume":"19","author":"Geerts","year":"2023","journal-title":"J. Nurse Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000528566","article-title":"Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment","volume":"15","author":"Mastropaolo","year":"2023","journal-title":"Case Rep. Neurol."},{"key":"ref_45","unstructured":"(2024, October 20). Long-COVID Richtlinie. Available online: https:\/\/www.g-ba.de\/downloads\/62-492-3451\/LongCOV-RL_2023-12-21_iK-2024-05-09.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(24)00216-0","article-title":"Long COVID and SARS-CoV-2 persistence: New answers, more questions","volume":"24","author":"Buonsenso","year":"2024","journal-title":"Lancet Infect Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: Major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","article-title":"Mechanisms of long COVID and the path toward therapeutics","volume":"187","author":"Peluso","year":"2024","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Leng, A., Shah, M., Ahmad, S.A., Premraj, L., Wildi, K., Li Bassi, G., Pardo, C.A., Choi, A., and Cho, S.M. (2023). Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells, 12.","DOI":"10.3390\/cells12050816"},{"key":"ref_50","first-page":"e29613","article-title":"Nephrotic Syndrome in Adult Patients With COVID-19 Infection or Post COVID-19 Vaccine: A Systematic Review","volume":"14","author":"Cancarevic","year":"2022","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e3286","DOI":"10.6061\/clinics\/2021\/e3286","article-title":"Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients","volume":"76","author":"Finsterer","year":"2021","journal-title":"Clinics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s12026-022-09316-6","article-title":"Guillain-Barr\u00e9 syndrome in association with COVID-19 vaccination: A systematic review","volume":"70","author":"Abolmaali","year":"2022","journal-title":"Immunol. Res."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1378\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:48:59Z","timestamp":1760114939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["vaccines12121378"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12121378","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}